Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915897 · ClinicalTrials.gov registry record
Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
A clinical trial, sponsored by Sanguine Biosciences.
- Terminated
- Registry status
- 6
- Enrollment target
NCT05915897: Clinical Trial study, sponsored by Sanguine Biosciences.
NCT05915897 is a clinical trial that was terminated before completion, run by Sanguine Biosciences. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05915897 was terminated before completion, sponsored by Sanguine Biosciences.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Chronic Granulomatous Disease (CGD). The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.
Primary Outcome
Participants have been diagnosed with Chronic Granulomatous Disease (CGD)
Interventions
- DIAGNOSTIC_TEST Specimen Donation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2024-03-25 |
Why NCT05915897 stopped before completion
NCT05915897 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Specimen Donation is the first listed.
NCT05915897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05915897 about?
NCT05915897 is a clinical study titled "Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)". The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Chronic Granulomatous Disease (CGD). The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and m...
What is the current status of trial NCT05915897?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2023-05-23. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT05915897?
The interventions under investigation include: Specimen Donation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05915897?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI